BREAKING: Futures Mixed; Musk Sells More Tesla Stock

The Relative Strength (RS) Rating for Dynavax Technologies (DVAX) moved into a new percentile Wednesday, as it got a lift from 63 to 76.
X When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
IBD’s proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock’s price performance over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an RS Rating of above 80 as they launch their biggest runs. See if Dynavax Technologies can continue to show renewed price strength and clear that threshold.
Looking For Winning Stocks? Try This Simple Routine
Dynavax Technologies is now considered extended and out of buy range after clearing a 10.45 buy point in a first-stage cup with handle. See if the stock forms a new chart pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company posted 0% EPS growth in the latest quarterly report. Revenue increased 55%.
Dynavax Technologies earns the No. 15 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab ADR (GMAB) and Harmony Biosciences (HRMY) are also among the group’s highest-rated stocks.
Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use
YOU MAY ALSO LIKE:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD’s Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Identify Bases And Buy Points With Pattern Recognition From MarketSmith
12/04/2022 Dynavax Technologies sees its Relative Strength Rating enter the 80-plus level.
12/04/2022 Dynavax Technologies sees its Relative Strength Rating enter the 80-plus…
Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20!
Get market updates, educational videos, webinars, and stock analysis.
Learn how you can make more money with IBD’s investing tools, top-performing stock lists, and educational content.
Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice.
*Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices are not sourced from all markets.
Ownership data provided by Refinitiv and Estimates data provided by FactSet.
© 2000-2022 Investor’s Business Daily, LLC. All rights reserved

source

Related Articles